Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pregabalin for Prevention of Central Pain in SCI
NCT06066918Recruiting
- Sponsor
- Loewenstein Rehabilitation Hospital
- Start
- Jul 2021
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of pregabalin in Central pain syndrome (CPS) (2 arms), sponsored by Loewenstein Rehabilitation Hospital. Primary endpoints: Central pain development at 1 year and McGill Pain Questionnaire at 3 months. Started Jul 2021; status: recruiting.
02
Drugs
pregabalin
03
Conditions
Central pain syndrome (CPS)
Beyond the preview
Go deeper on NCT06066918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06066918.